Source: s3://data.kl3m.ai/documents/govinfo/USCOURTS/USCOURTS-casd-3_07-cv-00280/USCOURTS-casd-3_07-cv-00280-1/pdf.json

Nature of Suit Code: 830
Nature of Suit: Patent
Cause of Action: 28:1441 Petition for Removal- Breach of Contract

---

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28 Joint Motion To Protect Confidentiality of Discussions

DM_US:20991771_6 

REY LLP

Robert E. Gooding, Jr. (SBN 50617) 

Scott B. Garner (SBN 156728) 

Ryan E. Lindsey (SBN 235073) 

HOWREY LLP 

2020 Main Street, Suite 1000 

Irvine, California 92614 

Telephone: (949) 721-6900 

Facsimile: (949) 721-6910 

Email: goodingr@howrey.com 

Email: garners@howrey.com 

Email: lindseyr@howrey.com 

Kenneth S. Klein (SBN 129172) 

Foley & Lardner LLP 

402 West Broadway, Suite 2100 

San Diego, California 92101 

Telephone: (619) 234-6655 

Facsimile: (619) 234-3510 

Email: kklein@foley.com 

Attorneys for Defendant Foley & Lardner LLP 

UNITED STATES DISTRICT COURT 

SOUTHERN DISTRICT OF CALIFORNIA 

VAXIION THERAPEUTICS, INC., 

Plaintiff, 

vs.

FOLEY & LARDNER LLP 

Defendants.

)

)

)

)

)

)

)

)

)

)

)

Case No. 07CV00280 IEG (RBB) 

JOINT MOTION TO PROTECT 

CONFIDENTIALITY OF DISCUSSIONS 

AND ORDER 

 

Case 3:07-cv-00280-IEG-RBB Document 74 Filed 05/16/08 Page 1 of 6
1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28 -2- Joint Motion To Protect Confidentiality of Discussions

DM_US:20991771_6 

REY LLP

Plaintiff Vaxiion Therapeutics, Inc. (“Vaxiion”), Defendant Foley & Lardner LLP (“Foley”), 

and Third Party EnGeneIC PTY Ltd. (“EnGeneIC”) (collectively, the “Parties”), through their 

respective counsel, hereby stipulate and jointly move the Court as follows: 

 WHEREAS, Vaxiion filed a complaint against Foley on December 28, 2006 in the San Diego 

County Superior Court alleging, among other things, claims for legal malpractice in connection with 

the prosecution of foreign patent applications pertaining to minicell technology (the “Action”); 

WHEREAS, Foley removed the Action to the United States District Court for the Southern 

District of California on February 9, 2007; 

WHEREAS, Vaxiion alleges that, as a result of Foley’s negligence, it has lost certain foreign 

patent rights in minicell technology; 

WHEREAS, EnGeneIC has certain patent rights that may be of interest to Vaxiion;

WHEREAS, in the course of the Early Neutral Evaluation Conference overseen by Magistrate 

Judge Ruben B. Brooks, Vaxiion and Foley have discussed having a meeting with EnGeneIC to 

consider a possible business arrangement between Vaxiion and EnGeneIC that could lead to a 

resolution of the dispute between Vaxiion and Foley and a settlement of Vaxiion’s claims against 

Foley;

WHEREAS, notwithstanding that EnGeneIC and Vaxiion may be direct competitors in certain 

fields relating to minicells, EnGeneIC, through its counsel, has agreed to engage in such discussions 

with Vaxiion and Foley, and Vaxiion and Foley, through their respective counsel, have agreed to 

engage in such discussions with EnGeneIC and each other, but only on the condition that such 

discussions be treated as confidential on the one hand by Vaxiion and Foley (and also as between 

Vaxiion and Foley) as set forth in this Joint Motion and, on the other hand, by EnGeneIC as set forth in 

a separate Confidentiality and Non-Disclosure Agreement, and that nothing said or produced in such 

discussions be used in any subsequent proceeding on the one hand by Vaxiion and Foley (and also as 

between Vaxiion and Foley) as set forth in this Joint Motion and, on the other hand, by EnGeneIC as 

set forth in such separate Confidentiality and Non-Disclosure Agreement; and 

Case 3:07-cv-00280-IEG-RBB Document 74 Filed 05/16/08 Page 2 of 6
1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28 -3- Joint Motion To Protect Confidentiality of Discussions

DM_US:20991771_6 

REY LLP

 WHEREAS, Vaxiion and Foley agree that any concepts or information disclosed to them by 

EnGeneIC before or after the date of this Joint Motion about the minicell technology or about 

EnGeneIC’s plans to use the minicell technology are confidential and proprietary, and that the 

disclosure of such confidential and proprietary information would be damaging to EnGeneIC if it 

became public or made available to a further competitor; and that the use of such confidential and 

proprietary information of EnGeneIC by Vaxiion and/or Foley would be damaging to EnGeneIC. 

 NOW, THEREFORE, in consideration of the Parties’ willingness to meet, the Parties stipulate 

and agree, and move the court, as follows: 

1. For purposes of this Agreement, “EnGeneIC Proprietary information” includes, but is 

not limited to, ideas, concepts, development plans for existing, new or improved products or processes, 

data, formulae, techniques, designs, sketches, know-how, plans, drawings, specifications, samples, 

reports, findings, studies, unpublished U.S. or international patent applications (and their drafts), or 

inventions relating to minicell technology, and includes all information relating to minicells disclosed 

by EnGeneIC to Vaxiion in any form whether or not identified as proprietary by EnGeneIC.

2. Vaxiion and Foley agree to treat as confidential EnGeneIC Proprietary information 

exchanged during any meetings contemplated by this Agreement. Vaxiion and Foley further agree 

that, unless ordered to do so by a court of competent jurisdiction, Vaxiion or Foley may not disclose or 

use EnGeneIC Proprietary information without the express written consent of EnGeneIC. 

3. Vaxiion and Foley agree that this Agreement, any action taken pursuant to this 

Agreement, any information exchanged or statements made at or in connection with any discussions 

contemplated by this Agreement, and/or any EnGeneIC Proprietary information disclosed during any 

meetings contemplated by this Agreement, shall not be offered or received in evidence in any legal 

action or proceeding as an admission of liability, wrongdoing, or for any other purpose by either 

Vaxiion or Foley. Moreover, Vaxiion and Foley agree that EnGeneIC Proprietary information 

exchanged pursuant to or during the meetings shall not be offered or received into evidence before any 

administrative or judicial body as evidence of the patentability, enforceability, priority, or validity of 

Case 3:07-cv-00280-IEG-RBB Document 74 Filed 05/16/08 Page 3 of 6
1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28 -4- Joint Motion To Protect Confidentiality of Discussions

DM_US:20991771_6 

REY LLP

any of EnGeneIC’s current or future patent applications or patents pertaining to minicell technology, 

including without limitation, in proceedings such as district court litigations, or patent office 

proceedings such as interferences, reexaminations, protests, cancellations or oppositions. 

4. Vaxiion and Foley agree that this Agreement, any action taken pursuant to this 

Agreement, and/or any information exchanged or statements made at or in connection with any 

discussions contemplated by this Agreement shall not be offered or received in evidence in any legal 

action or proceeding as an admission of liability, wrongdoing, or for any other purpose by either 

Vaxiion or Foley. 

5. Nothing hereinabove contained shall deprive Foley and Vaxiion of the right to use or 

disclose any information: 

a) which is, at the time of the disclosure, known to the trade or the public, as 

evidenced by written or other tangible evidence; 

b) which becomes at a later date known to the trade or the public, as evidenced by 

written or other tangible evidence, through no fault of Foley or Vaxiion, and then only after 

said later date; 

c) which is possessed by Foley or Vaxiion, as evidenced by Foley or Vaxiion’s 

written or other tangible evidence, before receipt thereof from the meetings; PROVIDED 

however that nothing in this subsection c) shall affect any information possessed by Foley 

prior to or acquired after the present Joint Motion due to Foley's prior or concurrent 

representation of EnGeneIC, which information shall continue to be kept confidential and 

subject to the attorney client privilege as otherwise required by any and all code(s) of 

professional responsibility by which Foley is bound; 

d) which is received by Foley or Vaxiion pursuant to any valid method of 

discovery in a legal proceeding, except where such information is covered by a protective 

order, in which case use of such information is limited by the terms of such protective order; 

Case 3:07-cv-00280-IEG-RBB Document 74 Filed 05/16/08 Page 4 of 6
1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28 -5- Joint Motion To Protect Confidentiality of Discussions

DM_US:20991771_6 

REY LLP

e) which is disclosed to Foley or Vaxiion in good faith by a third party who is 

lawfully in possession of such information and is under no duty to maintain the confidentiality 

of such information; or 

f) which was developed by Foley or Vaxiion independently of information 

received under this Agreement, as evidenced by written or other tangible evidence, without 

violating any obligations contained in this Agreement. 

6. EnGeneIC does not by this Agreement agree to submit to the jurisdiction of the United 

States District Court for the Southern District of California for the purpose of enforcing the terms of 

the proposed Order Protecting Confidentiality of Discussions. 

IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by a duly 

authorized representative. 

 Vaxiion Therapeutics, Inc. 

By: ________________________ 

Name: ________________________ 

Title: ________________________ 

 Date: ________________________ 

EnGeneIC Pty. Ltd. 

By: ________________________ 

Name: ________________________ 

Title: ________________________ 

 Date: ________________________ 

Foley & Lardner LLP

 By: ________________________ 

 Name: ________________________ 

 Title: ________________________ 

 Date: ________________________ 

Case 3:07-cv-00280-IEG-RBB Document 74 Filed 05/16/08 Page 5 of 6
1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28 -6- Joint Motion To Protect Confidentiality of Discussions

DM_US:20991771_6 

REY LLP

IT IS NOW HEREBY STIPULATED AND AGREED, by the Parties’ request, through their 

counsel, as follows: 

1. For good cause shown, the Court grant the Parties’ Joint Motion, and enter an order 

setting forth the terms stipulated to above to protect the confidentiality of discussions. 

February __, 2008 Respectfully Submitted, 

 s/Scott B. Garner 

 Scott B. Garner 

Howrey LLP 

 Attorneys for Defendant Foley & Lardner LLP 

 s/Karen R. Frostrom 

 Karen R. Frostrom 

Thorsnes Bartolotta McGuire 

 Attorneys for Plaintiff Vaxiion Therapeutics, Inc. 

 s/Jorge Goldstein 

 Jorge Goldstein 

 Sterne Kessler, Golstein & Fox P.L.L.C. 

 Attorneys for Third Party EnGeneIC PTY PLC 

ORDER

 The foregoing is approved and shall be the Order of the Court. 

DATED: May 16, 2008 

 

 United States Magistrate Judge 

 

United States Magistrate Judge

Case 3:07-cv-00280-IEG-RBB Document 74 Filed 05/16/08 Page 6 of 6